Novo Nordisk A/S: Transaction in Own Shares

February 17, 2009 |

2 min read

BAGSVÆRD, DENMARK--(Marketwire - February 16, 2009) - Novo Nordisk A/S - Share repurchase programme

On 29 January 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.

Since the announcement as of 9 February 2009, the following transactions have been made under the programme:

 Number of Average Transaction shares purchase price value, DKK Accumulated, last announcement 537,500 165,995,650 9 February 2009 75,000 302.71 22,703,250 10 February 2009 75,000 305.47 22,910,250 11 February 2009 75,000 301.88 22,641,000 12 February 2009 75,000 305.38 22,903,500 13 February 2009 75,000 311.55 23,366,250 Accumulated under the programme 912,500 280,519,900

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 200,196 B shares in the period from 9 February 2009 to 12 February 2009. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 25,716,935 treasury shares, corresponding to 4.1% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.

Company Announcement no 9 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.